

October 19, 2020

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

Dear Sir/Madam,

Trading Symbol: ZOTA

Sub: Product Registration in Cambodia

Ref.: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; we would like to inform you that we, Zota Health Care Limited (the "Company") have received product registration licenses for below mentioned two products from the Ministry of Health, Cambodia.

| Sr. No. | Name of Product | Therapeutic Category |
|---------|---|-----------------------------|
| 1 | CDTEL-80 (Tablet – Each tablet contains Telmisartan 80mg) | Angiotensin II Antagonists |
| 2 | GMFIT (<i>Zota's Patented Product</i>) (Tablet – Each tablet contains Taurine 500mg, Glucosamine Sulfate 500mg, Methylsulfonylmethane 25mg, Racemethionine 100mg) | Arthritis & Pain Management |

We have received licenses for the aforementioned products for the validity period of five years; licenses for the products are also renewable. Company shall start exporting these products in Cambodia very soon.

This is for your information and record.

Thanking you,

Yours faithfully,

For Zota Health Care Limited



Ashvin Variya
(Company Secretary & Compliance Officer)
Place: Surat



Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com
CIN : L24231GJ2000PLCO38352

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122